A crucial role in the regulation of DNA replication is
played by
the highly conserved CDC kinase. The CDC7 kinase could serve as a
target for therapeutic intervention in cancer. The primary heterocyclic
substance is pyrazole, and its derivatives offer great potential as
treatments for cancer cell lines. Here, we synthesized the two pyrazole
derivatives: 4-(2-(4-chlorophenyl)hydrazinyl)-5-methyl-2-tosyl-1H-pyrazol-3(2H)-one
(PYRA-1) and 4-(2-(2,4-difluorophenyl)hydrazinyl)-5-methyl-2-tosyl-1H-pyrazol-3(2H)-one
(PYRA-2). The structural confirmation of both the compounds at the
three-dimensional level is characterized using single crystal X-ray
diffraction and density functional theory. Furthermore, the
in silico
chemical biological properties were derived using
molecular docking and molecular dynamics (MD) simulations. PYRA-1
and PYRA-2 crystallize in the P-1 (
a
= 8.184(9),
b
= 14.251(13),
c
= 15.601(15), α
= 91.57(8), β = 97.48(9), 92.67(9),
V
= 1801.1(3)
3, and
Z
= 2) and P2
1
/
n
(
a
= 14.8648(8),
b
= 8.5998(4),
c
= 15.5586(8), β = 116.47(7),
V
=
1780.4(19) 3, and
Z
= 4), space groups, respectively.
In both PYRA-1 and PYRA-2 compounds, C–H···O
intermolecular connections are common to stabilize the crystal structure.
In addition, short intermolecular interactions stabilizes with C–H···π
and π–π stacking. Crystal packing analysis was
quantified using Hirshfeld surface analysis resulting in C···H,
O···H, and H···H contacts in PYRA-1
exhibiting more contribution than in PYRA-2. The conformational stabilities
of the molecules are same in the gas and liquid phases (water and
DMSO). The docking scores measured for PYRA-1 and PYRA-2 with CDC7
kinase complexes are −5.421 and −5.884 kcal/mol, respectively.
The MD simulations show that PYRA-2 is a more potential inhibitor
than PYRA-1 against CDC7 kinase.